Twelve-month clinical outcomes after coronary stenting with the Genous Bio-engineered R Stent in patients with a bifurcation lesion: from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) registry Marcel A. Beijk a , Peter Damman a , Margo Klomp a , Pier Woudstra a , Sigmund Silber e , Manfred Grisold c , Expedito E. Ribeiro d , Harry Suryapranata b , Jaroslaw Wo ´ jcik f , Kui Hian Sim g , Jan G.P. Tijssen a and Robbert J. de Winter a on behalf of the e-HEALING investigators Background The e-Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth (e-HEALING) registry was designed to capture clinical data on the use of the endothelial progenitor cell capture stent (ECS) in routine clinical practice. In this analysis, we investigated the 12-month clinical outcomes in patients treated with an ECS for a bifurcation lesion. Methods The worldwide, prospective, nonrandomized e-HEALING registry aimed to enrol 5000 patients treated for coronary artery disease with one or more ECS between October 2005 and October 2007. Clinical follow-up was obtained at 1, 6, and 12 months. The primary endpoint was target vessel failure (TVF), defined as the composite of cardiac death, myocardial infarction, and target vessel revascularization at 12 months. Results A total of 573 patients were treated for at least one bifurcation lesion and were assessed in the current analysis. Baseline characteristics showed a median age of 65 years; 21% were diabetic patients and 36% had unstable angina. A total of 63% of the bifurcation lesions were located in the left artery descending and the mean stent length was 20.7 ± 12.6 mm. At 12 months, TVF was 12.7% and target lesion revascularization was 7.5%. Definite or probable stent thrombosis occurred in 1.7% of the patients. Moreover, one or more stents per lesion [hazard ratio (HR): 2.79, 95% confidence interval (CI): 1.60–4.86, P < 0.001], predilatation (HR: 0.39, 95% CI: 0.17–0.87, P = 0.023), and lesions located in the right coronary artery (HR: 4.56, 95% CI: 1.07–19.5, P = 0.041) were independent predictors of TVF. Conclusion In the e-HEALING registry, coronary bifurcation stenting with the ECS results in favorable clinical outcomes and low incidences of repeat revascularization and stent thrombosis. Coron Artery Dis 23:201–207  c 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins. Coronary Artery Disease 2012, 23:201–207 Keywords: bifurcation lesion, e-Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth, endothelial progenitor cell capture stent, Genous a Department of Cardiology, Academic Medical Center – University of Amsterdam, Amsterdam, b Isala Klinieken, Locatie Weezenlanden, Zwolle, The Netherlands, c Klinische Abteilung fur Kardiologie, Medizinische Universitatsklinik, Graz, Austria, d Incor, The Heart Institute of the University of Sa ˜ o Paulo, Sa ˜ o Paulo, Brazil, e Kardiologische Praxis und Praxisklinik, Munich, Germany, f Department of Cardiology, Medical University of Lublin, Lublin, Poland and g Sarawak General Hospital, Jalan Tun Ahmad Zaidi Adruce, Sarawak, Malaysia Correspondence to Robbert J. de Winter, MD, PhD, FESC, Department of Cardiology, Academic Medical Center – University of Amsterdam, B2-137, Meibergdreef 9, PO Box 22660, 1105 AZ Amsterdam, The Netherlands Tel: + 31 205 669 111; fax: + 31 206 962 609; e-mail: r.j.dewinter@amc.uva.nl Marcel A. Beijk, Peter Damman, and Margo Klomp contributed equally to the writing of this article. Received 18 August 2011 Revised 25 December 2011 Accepted 2 January 2012 Introduction The endothelial progenitor cell capture stent (ECS) is a novel stent technology with a ‘prohealing’ approach. The stent struts are coated with a biocompatible matrix with murine, monoclonal, antihuman CD34 + antibodies that are covalently attached. These antibodies specifically target the surface antigens present on circulating endothelial pro- genitor cells (EPC), thereby creating an immune affinity surface for preferentially capturing these circulating cells. After the EPCs are immobilized on the stent surface, it is hypothesized that these cells rapidly differentiate into a functional endothelial layer. This ‘prohealing’ technology may effectively inhibit stent-related thrombus formation and neointimal hyperplasia. The clinical safety and efficacy of the ECS was demonstrated in the Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth (HEAL- ING) First-In-Man [1] and HEALING II study [2,3] in noncomplex, de-novo coronary lesions with only 1 month of dual antiplatelet therapy (DAPT) prescribed. At 1 year, both studies showed favorable clinical outcomes. Several randomized studies evaluating different treatment strategies of bifurcation lesions have provided valuable insights. However, clinical outcomes after stenting of Therapy and prevention 201 0954-6928  c 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins DOI: 10.1097/MCA.0b013e328351550f Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.